Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma

(MedPage Today) -- In an analysis of the phase III CEPHEUS trial presented at the American Society of Hematology annual meeting, adding daratumumab (Darzalex) to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) significantly...